| | Application No. | Applicant(s) | _ |
|---|--|---|---|
| | 10/662,002 | PARK ET AL. | |
| Notice of Allowability | Examiner | Art Unit | _ |
| | Vickie Kim | 1614 | |
| The MAILING DATE of this communication appe All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI | (OR REMAINS) CLOSED in this apport or other appropriate communication GHTS. This application is subject to | plication. If not included will be mailed in due course. THIS | e |
| 1. \boxtimes This communication is responsive to <u>Examiner's amndment</u> | t requested on 11/10/04. | | |
| 2. The allowed claim(s) is/are 1,5-9 and 12. | | | |
| 3. \boxtimes The drawings filed on <u>12 September 2003</u> are accepted by | the Examiner. | | |
| 4. Acknowledgment is made of a claim for foreign priority un a) | been received. been received in Application No cuments have been received in this of this communication to file a reply ENT of this application. tted. Note the attached EXAMINER as reason(s) why the oath or declara t be submitted. on's Patent Drawing Review (PTO- a Amendment / Comment or in the Comment of the drawing the header according to 37 CFR 1.121(c) | national stage application from the complying with the requirements 'S AMENDMENT or NOTICE OF tion is deficient. 948) attached Office action of the back) of d). | |
| attached Examiner's comment regarding REQUIREMENT F Attachment(s) 1. ☑ Notice of References Cited (PTO-892) 2. ☑ Notice of Draftperson's Patent Drawing Review (PTO-948) | FOR THE DEPOSIT OF BIOLOGIC, 5. □ Notice of Informal P 6. ☑ Interview Summary Paper No./Mail Dat | AL MATERIAL. atent Application (PTO-152) (PTO-413), ie 11/10/04 | ` |
| 3. Information Disclosure Statements (PTO-1449 or PTO/SB/08) Paper No./Mail Date 12/2003 4. Examiner's Comment Regarding Requirement for Deposit of Biological Material | | ent of Reasons for Allowance VICKIE KIM PRIMARY FYARMER | |

Application/Control Number:

10/662,002 Art Unit: 1614

DETAILED ACTION

Priority

1. Acknowledgment is made of applicant's claim for foreign priority based on an application filed in PCT/KR02/00428 on 3/12/2001 and Korean application filed 3/12/2001. It is noted, however, that applicant has not filed a certified copy of the Korean application as required by 35 U.S.C. 119(b). Applicant is advised to submit certified copy to comply rule under 35 U.S.C. 119(a)-(d) to obtain the benefit of the filing date of a prior application filed in a foreign country.

Status of Application

1. The claims 1-12 are pending and presented for the examination. Due to restriction requirement/provisional election reply and allowable claimed subject matters found during the examination, both parties agreed on canceling non-elected claims(provisional) and the examiner's amendment that further accommodates all the changes to put this application under allowable condition is requested to expedite the prosecution. Detailed Examiner's Amendment is following.

EXAMINER'S AMENDMENT

2. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Application/Control Number:

10/662,002 Art Unit: 1614 Page 3

- 3. Authorization for this examiner's amendment was given in a telephone interview with Mr. Calson, John on 10/10/2004.
- 4. The application has been amended as follows:
 - a. Rewrite the claims 1 and 5 as following:
- ----- 1.(Currently amended) A therapeutic composition for topical application, consisting essentially of: a sphingolipid long-chain base present at from about 0.01 to 5.0% and lysophosphatidic acid present at from about 0.001 to 1.0%, wherein the shingolipid long-chain base is one or more selected from the group consisting of phytoshingosine, acetylphytosphingosine, tetraacetyl phytosphingosine, hexanoylphytoshingosine and acetylphytosphingosine phosphate.

Claim 5.(Currently amended) A therapeutic composition for topical application, consisting essentially of: 30 to 90% by weight of a substrate or a carrier for skin application; 0.01 to 5.0% by weight sphingolipid long-chain base; 0.001 to 1.0% by weight lysophosphatidic acid; and 1.0 to 40% by weight of organic or inorganic additives, wherein the shingolipid long-chain base is one or more selected from the group consisting of phytoshingosine, acetylphytosphingosine, tetraacetyl phytosphingosine, hexanoylphytoshingosine and acetylphytosphingosine phosphate. ---

b. Claims 2-4 and 10-11. (Canceled)

Reasons for allowance

- 5. Claims 1, 5-9 and 12 are allowable over the prior art.
- 6. It is noted that a potential divisional application that is drawn to a invention containing non-elected invention(i.e. claims 10-11) will not be subjected to double patenting rejection over the instant application.
- 7. The following is an examiner's statement of reasons for allowance: All the claimed subject matter is novel and not obvious over any prior art of the record. US 6348201B2(Murata et al) teaches an external composition for skin comprising a

10/662,002

Art Unit: 1614

sphingoglycolipid having the specific formula I as recited in abstract. It also teaches various additives such as phytosphingosine(Col. 12, lines 41), lysophosphatidyl choline, phosphatidic acid, etc (Col. 10, lines 60-67). However, it fails to teach a combination of consisting essentially of 0.01 to 5% of sphingolipid long chain base such as phytosphingosine and about 0.001-1% of lysophosphatidic acids used as only active agent for topical composition. Furthermore, there is no motivation or suggestion to make such combination and thus, the claimed subject matter is considered to be patentably distinct over the prior art of the record.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

- 8. All the pending claims 1, 5-9 and 12 are allowed.
- Any inquiry concerning this communication or earlier communications from the examiner should be directed to Vickie Kim whose telephone number is 571-272-0579.
 The examiner can normally be reached on Tuesday-Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low can be reached on 571-272-0953. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Application/Control Number:

10/662,002 Art Unit: 1614

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-2 (7-9197 (toll-free).

Primary Patent Examiner

November 15, 2004

Art unit 1614